Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Soo Peang Khor"'
Autor:
Soo-Peang Khor, Ann Hsu
Publikováno v:
Current Clinical Pharmacology. 2:234-243
Levodopa, a prodrug of dopamine, remains to be one of the main drugs in the treatment of Parkinson's disease. All current levodopa products are formulated with aromatic amino acid decarboxylase inhibitors such as carbidopa or benserazide to prevent t
Autor:
Leo M. Albert, Chih-Ming Leo Tseng, Andrew J. Dorner, Page Bouchard, Ron L. Peterson, James C. Keith, Soo-Peang Khor
Publikováno v:
Pharmaceutical Research. 17:482-485
Recently, rhIL-11 was developed as an enteric-coated In Vivo Absorption Properties of multiparticulate formulation for oral dosing of patients with Orally Administered Recombinant inflammatory bowel disease. Therefore, we conducted a series of PK stu
Publikováno v:
Pharmaceutical Research. 15:1643-1646
Autor:
Eric K. Rowinsky, Marna Doucette, Ross C. Donehower, Sharyn D. Baker, Louise B. Grochow, Alex A. Adjei, Tom Spector, Dennis A. Noe, John A. Hohneker, Soo Peang Khor, S E Sartorius
Publikováno v:
Journal of Clinical Oncology. 14:3085-3096
PURPOSE To study the absolute bioavailability and pharmacokinetics of an oral solution of fluorouracil (5-FU) in patients treated with 776C85, an oral inactivator of dihydropyrimidine dehydrogenase (DPD), and to evaluate the feasibility of administer
Autor:
Natarajan Raghunand, David Brown Wilson, Soo-Peang Khor, Olivia Longacre, Jason D. Lickliter, Howard P. Hendrickson, Evan C. Unger
Publikováno v:
Journal of Clinical Oncology. 33:TPS2078-TPS2078
TPS2078 Background: Post-resected glioblastoma multiforme (GMB) patients were treated with dodecafluoropentane emulsion (DDFPe) to evaluate the pharmacokinetics (PK), safety and potential survival ...
Autor:
Marina W.H. Shen, Mario D. Gonzalez, John C. McKew, Wen Zhang, Tam Steve Yik-Kai, Howard Sard, Kun Wu, Soo Peang Khor, Paresh Thakker, Mark L. Behnke, Shanghao Liu, Megan A. Foley, Frank Lovering, Fuk-Wah Sum, Anu Mahadevan, James D. Clark
Publikováno v:
Journal of medicinal chemistry. 49(1)
Compound 1 was previously reported to be a potent inhibitor of cPLA(2)alpha in both artificial monomeric substrate and cell-based assays. However, 1 was inactive in whole blood assays previously used to characterize cyclooxygenase and lipoxygenase in
Publikováno v:
Journal of pharmacological and toxicological methods. 47(1)
Introduction: The purpose of this study was to evaluate the feasibility of using gel electrophoresis combined with autoradiographic image analysis for quantitating protein drug concentrations in biological fluid for pharmacokinetic studies. Methods:
Autor:
Go Ning, Denise Nazzal, Lyssa Villarreal, Preeti Pattamata, Soo-Peang Khor, Karen Delavan-Boorsma, Tong Lin, Robert J. Tressler
Publikováno v:
Cancer Research. 70:3202-3202
Telomerase activation is a hallmark of cancer and is critical for dysregulated cell proliferation and cell immortality. Increased telomerase activities were detected in essentially all epithelium derived cancers tested up-to-date and in many hematolo
Publikováno v:
Journal of pharmaceutical sciences. 80(11)
We evaluate here an area term, the area under the rate of change of concentration-time curve (AURC), which allows the determination of the initial or central volume of distribution (V 1 ). It has previously been shown that AURC is equal to the sum of
Autor:
Jennifer A. Smith, Carol Ann Huff, Mohamad A. Hussein, Laurence Elias, Asher A. Chanan-Khan, Nikhil C. Munshi, Soo-Peang Khor, Benedetti Fabio
Publikováno v:
Blood. 112:3688-3688
Telomerase over-expression is the predominant mechanism by which cancer cells maintain adequate telomere length to achieve immortalization. Telomere length is often decreased and telomerase activity is often increased in MM. GRN163L is a 13-mer oligo